Reproduced from original article:
https://ianbrighthope.substack.com/p/mrna-influenza-vaccine-in-australia
Ian Brighthope     Sep 08, 2026

Here is how CHAT GPT Views it. Please note it avoids my first question whether or not it is an mRNA vaccine. I had to ask it a second time.

CHATS response:
Short answer: Moderna’s new vaccine, MFLUSIVA, is a legitimate FDA-approved seasonal flu vaccine—not an emergency-use product. It is a reasonable option for some adults, but the best choice depends mainly on age.

• Under 50: It is not approved; use another age-appropriate flu vaccine.
• Age 50–64: MFLUSIVA is a reasonable option. In a roughly 40,000-person trial, laboratory-confirmed flu occurred in 2.0% with MFLUSIVA versus 2.8% with a standard-dose flu vaccine—a 26.6% relative improvement, not 26.6% absolute protection.
• Age 65+: I would currently lean toward one of CDC’s established preferred vaccines—Fluzone High-Dose, Flublok, or Fluad—unless unavailable or your clinician recommends MFLUSIVA. Its approval in this age group was accelerated based primarily on stronger antibody responses versus high-dose vaccine; whether it prevents more actual illness than high-dose vaccine remains under study through 2029–2030. FDA approval letter CDC guidance

Expect more short-term reactions than with conventional flu shots: injection-site pain occurred in approximately 63–69%, fatigue in 42–48%, and headache in 34–42%; reactions generally lasted about two days. Serious adverse-event rates were similar to comparator vaccines. FDA identified no myocarditis/pericarditis cases within 42 days in the clinical safety database, although monitoring for rare events continues. FDA prescribing information FDA clinical review

It contains no influenza virus, egg protein, antibiotics, or preservatives and cannot cause influenza. Avoid it following a severe allergy to one of its components—particularly discuss previous PEG or mRNA-vaccine anaphylaxis—and seek individualized advice if you developed Guillain–Barré syndrome within six weeks of a previous flu vaccine or are immunocompromised.

For most adults, September or October is preferable to August because protection can wane. If the choice is MFLUSIVA versus missing flu vaccination entirely, an eligible person without a contraindication should generally take the available vaccine.

My second question: is it mRNA?

Yes. MFLUSIVA (mRNA‑1010) is an mRNA flu vaccine made by Moderna—the first FDA-approved mRNA influenza vaccine.

It delivers temporary mRNA instructions for cells to produce influenza hemagglutinin proteins from three flu strains. The immune system then learns to recognize them. It contains no influenza virus, cannot cause flu, and the mRNA does not enter the cell nucleus or alter DNA. This latter claim is BS.

Haemagglutinin proteins will probably be more damaging than the spike protein of the covid vaccine.

Moderna has submitted two products to the TGA:

• mFLUSIVA (mRNA-1010) — a standalone mRNA influenza vaccine proposed for people aged 50 years and over. The TGA accepted the application in February 2026, but it remains under evaluation, not registered or approved. TGA: mFLUSIVA
• mCOMBRIAX — a combined mRNA influenza–COVID-19 vaccine for people aged 50 years and over. Its application was accepted in March 2026 and also remains under evaluation. TGA: mCOMBRIAX

The TGA’s list of seven influenza vaccines available in Australia for the 2026 season contains conventional egg-based, cell-culture or live-attenuated products—none is an mRNA influenza vaccine. TGA: 2026 seasonal influenza vaccines

Therefore, an mRNA influenza vaccine may be used in Australia only within an authorised clinical trial or exceptional access pathway—not as a routinely registered influenza vaccine. Moderna’s mFLUSIVA was approved in the United States in August 2026, but that approval does not apply in Australia.

But wait, mFLUSIVA and mCOMBRIAX are still under evaluation by the TGA. I believe they will be approved for use in Australia before the next ‘flu season’. If so, the side effects mentioned above will mean more vaccine caused deaths, turbo cancers and auto immune diseases will his our Australian population even harder than the Covid poisons. A reminder, expect more short-term reactions than with conventional flu shots: injection-site pain occurred in approximately 63–69%, fatigue in 42–48%, and headache in 34–42%. These are all critical symptoms pointing in a negative biological direction.